Summary
Researchers aimed to discover whether LMTM [Leuco-methylthioninium bis(hydromethanesulfonate] might be safe and effective for slowing disease progression in patients with mild to moderate Alzheimer’s Disease. LMTM had previously been found to work as a selective inhibitor of tau protein aggregation, in vitro and in transgenic mouse models.
Results from their 15-month randomised controlled double-blind trial, held at 115 centres in 16 countries, were negative; with no evident benefit of LMTM as an add-on treatment for patients with mild to moderate Alzheimer’s Disease.
Full Text Link (Note: This article requires a suitable Athens password, a journal subscription or payment for access).
Reference
Gauthier, S. Feldman, HH. [and] Schneider, LS. [et al] (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. November 15th 2016. [Epub ahead of print].
